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Abstract: Primary and secondary mucinous tumors can involve the
ovaries and have similar histologic appearances. The differential di-
agnosis is important for surgical and chemotherapeutic treatment and
for the prognosis, but often it is extremely difficult. This article dis-
cusses an immunohistochemical panel that includes carcinoembry-
onic antigen (CEA), cytokeratin (CK) 7, CK20, CA125, CA19.9, and
a new marker, CDX-2, for the distinction between primary ovarian
mucinous carcinomas and metastatic (intestinal) ovarian tumors.
Forty-three cases representing primary and secondary ovarian tumors
were considered and consisted of 14 primary mucinous ovarian car-
cinomas (PMOCs) and 29 secondary (intestinal) ovarian tumors (SI-
OTs). Fisher exact test was performed to evaluate the reliability of the
respective antibodies to discriminate between PMOCs and SIOTs.
CDX-2 was diffusely positive in all SIOTs and was expressed focally
in 3 cases (21.42%) of PMOCs. CK7 was diffusely positive in 13
cases (44.82%) of SIOTs and in 13 cases (92.85%) of PMOCs. CK20
was diffusely positive in 17 cases (58.62%) of SIOTs and in 6 cases
(42.85%) of PMOCs. CEA was diffusely positive in 28 cases
(96.55%) of SIOTs and in 12 cases (85.71%) of PMOCs. CA19.9 was
positive in all SIOTs and in 12 cases (85.71%) of PMOCs. CA125
was positive in 3 cases (10.34%) of SIOTs and in 4 cases (28.57%) of
PMOCs. CK7 and especially CDX-2, a specific and sensitive marker,
can aid pathologists in making a differential diagnosis (P = 0.003 and
P < 0.0005, respectively), whereas CEA, CK20, CA125, and CA19.9
markers are not high enough to distinguish between primary and sec-
ondary mucinous ovarian tumors.
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Mucinous metastases to the ovaries are more frequent thanprimary mucinous ovarian carcinoma (PMOC).1 Pri-
mary mucinous carcinomas appear to account for approxi-
mately 3.6% of ovarian epithelial neoplasms, 12% of ovarian
mucinous neoplasms, and 11% of ovarian carcinomas.2
Ovarian mucinous carcinomas occur in patients in the
4th to 7th decades. As many as 63% of the cases are Interna-
tional Federation of Gynecology and Obstetrics (FIGO) stage
I, and nearly all stage I cases have unilateral ovarian involve-
ment.3 Therefore, these women do not generally present signs
and symptoms of abdominal carcinomatosis, but the clinical
presentation is usually that of a large mass and abdominal dis-
tension. The proportion of stage I cases varies widely among
studies because of the difficulty in distinguishing intraepithe-
lial carcinomas from invasive carcinomas.4
Before making a diagnosis of mucinous carcinoma of
the ovary, it is imperative to exclude metastatic mucinous car-
cinoma. Mucinous adenocarcinomas of the pancreas, biliary
tract, colon, appendix, and cervix can mimic ovarian mucinous
carcinomas.5–8 Approximately 40% of adenocarcinoma me-
tastases to the ovary originate from the colon.9 It may be dif-
ficult to differentiate between primary and metastatic lesions
according to clinical and histopathologic aspects, but the dif-
ferential diagnosis is decisive for the surgical and chemothera-
peutic treatment and for the prognosis.
Sometimes the clinical history of a patient can help in the
exact diagnosis, but a negative anamnesis for neoplastic dis-
ease is not helpful, because sometimes metastases can antici-
pate a primary tumor. A recent report indicates a rule that cor-
rectly classified 90% of the neoplasm. It classifies all bilateral
mucinous carcinomas as metastatic and unilateral mucinous
carcinomas 10 cm or greater as primary.10
Cdx genes are homeobox genes necessary for intestinal
organogenesis and encode for nuclear transcription factors in-
volved in proliferation and differentiation of intestinal epithe-
lial cells in fetal and adult tissue.11 CDX-2 is expressed in nor-
mal colonic epithelia and most colorectal adenocarcino-
mas.12,13
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The aim of the present study was to evaluate whether the
immunohistochemical expression of CDX-2 in a series of mu-
cinous ovarian carcinomas and a series of secondary ovarian
carcinoma could be a reliable marker for identifying colorectal
metastases from primary ovarian tumors and whether this
marker could be added to an immunohistochemical panel of
specific markers useful in this differential diagnosis.
MATERIALS AND METHODS
Case Selection
The files of the Department of Human Pathology and
Oncology of the University of Florence were searched from
1990 to 2002 for the diagnosis of ovarian mucinous tumors.
From these neoplasias, 14 cases of primary mucinous
carcinoma of the ovary and 29 cases of ovarian metastases
from intestinal carcinoma were selected to be evaluated in the
current analysis. Of these 43 cases, histologic material, clinical
data, and follow-up were available. Clinical data available for
each patient included age, previous medical history, surgical
treatment, disease stage, adjuvant therapy if performed, and
follow-up.
All microscopic slides were reviewed without knowl-
edge of the previous medical history or the clinical outcome.
The age range of the patients with primary ovarian tumor
was between 33 and 84 years (average age, 52.23 years; me-
dian, 53 years). None of these women had a medical history of
surgical operation for neoplastic disease. The 14 patients un-
derwent surgical treatment of abdominal hysterectomy, bilat-
eral salpingo-oophorectomy, appendectomy, and omentec-
tomy with careful examination of all serosal surface and biop-
sies of any suspected lesions. All patients were staged
according to the modified staging system of the International
Federation of Gynecology and Obstetrics for malignant sur-
face epithelial-stromal tumors. Twelve cases were FIGO stage
I, and 2 cases were stage III.14 Twelve of the 14 cases of pri-
mary ovarian carcinomas were unilateral with a size range of 6
to 15 cm, whereas 2 cases had bilateral masses with peritoneal
metastasis outside the pelvis. On these 14 patients, a postop-
erative chemotherapeutic treatment was performed indepen-
dently of the presence or absence of residual disease. The fol-
low-up period was 26 to 143 months.
The age range of the patients with ovarian metastases
was between 33 and 86 years (average age, 61.31 years; me-
dian, 67 years). In 3 of these patients (13.63%), secondary
ovarian neoplasias were metachronous in regard to colon car-
cinoma. They had undergone surgical treatment of colectomy
with regional lymphadenectomy and postoperative chemo-
therapeutic treatment of a primary intestinal carcinoma 18, 22,
and 30 months previously. Soon afterward, these patients un-
derwent surgical treatment of abdominal hysterectomy, bilat-
eral salpingo-oophorectomy, and omentectomy for an ovarian
mass. In 25 patients (81.81%) with secondary ovarian tumor,
the ovarian metastases were synchronous with intestinal car-
cinoma. These 25 women had undergone surgical treatment of
colectomy with regional lymphadenectomy, appendectomy,
abdominal hysterectomy, bilateral salpingo-oophorectomy,
and omentectomy, and subsequent chemotherapeutic treat-
ment. In the remaining patient of our series of cases, the sec-
ondary ovarian tumor was anticipated in regard to the colon
carcinoma. This woman had undergone abdominal hysterec-
tomy, bilateral salpingo-oophorectomy, appendectomy, and
omentectomy for an ovarian mass, and 23 months thereafter,
she underwent a colectomy with regional lymphadenectomy
for intestinal carcinoma.
Immunohistochemistry
The specimens were obtained by surgical resection in all
cases and fixed in 10% formalin before being processed in par-
affin. For immunohistochemical analysis, a representative sec-
tion of each lesion was selected.
The immunohistochemical study was performed using
the streptavidin-biotin-peroxidase method (UltraVision kit;
Lab Vision, Fremont, CA) with diaminobenzidine as chromo-
gen and hematoxylin as nuclear counterstain with antibodies
anti–CDX-2 (clone 7C7/D4; Bio-Genex, San Ramon, CA;
1:100 dilution; with Immunostainer Genomix Bio-Genex and
MW antigen retrieval for 30 pH 6 with citrate buffer), anticy-
tokeratin 20 (clone IT-Ks20.8; Bio-Genex; 1:60 dilution; with
Immunostainer Nexes Ventana and protease digestion with
phosphate buffer solution), anticytokeratin 7 (clone OV-
TL12/30; Bio-Genex; 1:800 dilution; with Immunostainer
Nexes Ventana and proteasi antigen retrieval with phosphate
buffer solution), anti-CA125 (clone M11; CISbio International
France; with Immunostainer Nexes Ventana), anti-CA19.9
(clone NS19.9; CISbio International France; with Immuno-
stainer Nexes Ventana), and anticarcinoembryonic antigen
(cd66e; clone 12-140-10; Novocastra, UK; 1:500 dilution;
with Immunostainer Nexes Ventana and proteasi antigen re-
trieval with phosphate buffer solution).
The negative controls were performed by omitting the
primary antibodies and by substituting the primary antibodies
with nonimmune mouse sera. Appropriate positive and nega-
tive controls were run simultaneously. Sections of strongly
positive cytokeratin (CK) 7 columnar epithelium cervical,
positive CK20 and carcinoembryonic antigen (CEA) colonic
adenocarcinoma, positive CDX-2 intestinal epithelium,
CA125-positive serous ovarian carcinoma, and CA19.9-
positive pancreatic carcinoma were used as positive control
tissues for CK7, CK20, CEA, CDX-2, CA125, and CA19.9,
respectively.
The immunohistochemically stained sections were
evaluated without previous knowledge of the clinical outcome
of each patient.
Brown staining of antibody-specific CDX-2 of the
nucleus was considered positive. Brown staining of cytoplasm
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of antibody-specific CK20 and CK7 was considered positive.
Lesions were considered immunoreactive with CEA if the cy-
toplasm of columnar epithelial cells showed immunoreactivity
equal to glycocalyx staining in intensity. Lesions were consid-
ered immunoreactive with CA125 and CA19.9 if they showed
staining of the cell membrane, especially on the apical site. The
intensity of immunostaining was classified in 3 grades: no
staining, weak staining, and strong staining.
Statistical Analysis
Statistical analysis was performed to evaluate the reli-
ability of the antibodies to discriminate between primary ovar-
ian carcinoma and ovarian metastases.
The statistical analysis was performed using the Fisher
exact test. P value 0.05 was considered statistically signifi-
cant.
RESULTS
CDX-2 was diffusely expressed in the nucleus of all
cases of secondary (intestinal) ovarian tumor (100%; Fig. 1),
whereas the majority (78.57%) of primary ovarian mucinous
carcinomas were CDX-2–negative (Fig. 2), and CDX-2 was
expressed focally in the nucleus of only 3 cases (21.42%; Fig.
3) of PMOCs (P < 0.0005). Of these 3 cases of CDX-2 focally
positive PMOCs, 2 were positive for CK7, CK20, CEA, and
CA19.9 and negative for CA125, and 1 case was negative for
CK7, CK20, CEA, CA19.9, and CA125.
The expression of CEA antigen was identical for both
types of tumors: it was expressed in both cytoplasm and on the
cell membrane strongly in 28 cases of secondary ovarian tu-
mors (96.55%) and 12 cases of PMOCs (85.71%; P = 0.24).
CK7 and CK20 showed a cytoplasmic localization in carci-
noma cells: CK7 showed positive staining in 13 cases of sec-
ondary ovarian tumors (44.82%) and in 13 cases of PMOCs
(92.85%), whereas CK20 showed positive staining in 17 cases
of secondary ovarian tumors (58.62%) and in 6 cases of
PMOCs (42.85%; P = 0.003 and P = 0.51, respectively).
CA125 and CA19.9 predominantly showed staining in the cell
membrane, especially on the apical site. Occasionally, some
expression was found in the cytoplasm. CA125 was expressed
FIGURE 3. CDX-2 was expressed focally in the nucleus of only
3 (21.42%) cases of PMOCs (original magnification 40).
FIGURE 1. Metastasis of colorectal adenocarcinoma in the
ovary. CDX-2 was diffusely expressed in the nucleus of the
secondary (intestinal) ovarian tumor (original magnification
40).
FIGURE 2. The majority (78.57%) of primary ovarian mucin-
ous carcinomas were CDX-2–negative (original magnification
40). Sections of secondary (intestinal) ovarian tumors and of
primary ovarian carcinoma were run simultaneously.
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in 3 cases of secondary ovarian tumors (10.34%) and in 4 cases
of PMOCs (28.57%), and CA19.9 was expressed in all cases of
secondary ovarian tumors (100%) and in 12 cases of PMOCs
(85.71%; P = 0.19 and P = 0.1, respectively).
The results of the immunohistochemical studies are
summarized in Table 1.
DISCUSSION
Often the diagnosis of a metastatic tumor to the ovaries is
missed by the pathologist because the existence of a present or
previous tumor in another side is either not known or disre-
garded.15,16 Pathologists need to be extremely cautious when
evaluating ovarian mucinous tumors, because secondary ovar-
ian carcinomas of intestinal origin may closely simulate pri-
mary carcinomas of the ovary, and they may be much larger
than intestinal primary tumor.17
The overall incidence of metastases of colorectal carci-
noma to the ovaries is 10% when malignant ovarian tumors are
encountered at the time of surgery.18,19
The histologic distinction between a secondary (intesti-
nal) ovarian neoplasm and a primary ovarian mucinous adeno-
carcinoma can be extremely difficult and sometimes impos-
sible: as many as 45% of secondary ovarian tumors are clini-
cally seen to be primary ovarian carcinomas, and many are
misinterpreted as such on pathologic examination, even when
there is a known intestinal carcinoma.5
The difficulty of differential diagnosis on histologic
grounds alone between primary ovarian carcinoma and colo-
rectal metastases to ovaries has prompted an intensive search
for immunohistochemical markers that can help distinguish
between these 2 lesions.
Carcinoembryonic antigen is a highly glycosylated cell
surface protein overexpressed in a variety of human tumors,
such as colorectal, gastric, pancreatic, ovarian, breast, and
nonsmall cell lung carcinomas.20 It is characterized by an on-
cofetal pattern of developmental expression. Several studies
have demonstrated that CEA immunostaining is of no value in
the differentiation between secondary ovarian tumors showing
a mucinous pattern and PMOC, because both show equally
strong staining.5,21
CA125 and CA19.9 are not discriminatory markers be-
tween ovarian mucinous carcinoma and intestinal carci-
noma.21–23
Cytokeratin 7 and CK20 have been suggested as immu-
nohistochemical discriminators between ovarian masses of
müllerian type (CK7+, CK20–) and of intestinal type (CK7–,
CK20+), but whereas the discrimination of the nonmucinous
carcinomas does not raise any problems, the distinction be-
tween a mucinous colonic and a mucinous ovarian carcinoma
is more difficult. A few mucinous ovarian tumors resemble
intestinal carcinomas in their immunohistochemical staining
pattern (CEA+, CK20+, CK7–), and some colonic carcinomas
expressed CK7.21 A recent study reported that there are metas-
tases from colorectal carcinomas with CK7+/CK20– immuno-
phenotype and with CK7+/CK20+ immunophenotype, so
these immunohistochemical stainings are not helpful for the
differential diagnosis.24 An important element in the evalua-
tion of positive or negative staining is that focal expression of
CK7 and CK20 should be given the same significance as nega-
tive immunostaining because of the steady increase of anti-
body sensitivity as a result of improved pretreatment meth-
ods.25
From these data, it was discovered that the specificity of
CEA, CK20, CK7, CA125, and CA19.9 markers is not suffi-
ciently high in distinguishing secondary (intestinal) ovarian tu-
mors from primary ovarian mucinous carcinomas. The current
study, which combines all 3—morphologic data, clinical data,
and immunohistochemical assessment of malignant tumors of
the ovary—was undertaken to determine whether the introduc-
tion of a new monoclonal antibody to an immunohistochemi-
cal panel, such as CDX-2, can help us in the differential diag-
nosis of mucinous ovarian carcinoma from the most frequent
CDX-2–positive secondary (intestinal) ovarian lesions.26
In a recent study on metastases to the lungs, Barbareschi
et al24 analyzed 5 cases of secondary pulmonary mucinous tu-
mors from ovarian neoplasia that were all CDX-2–positive,
and Werling et al27 found CDX-2 high-level expression in mu-
cinous ovarian neoplasias that were also villin-positive.
On the other hand, our immunohistochemical data show
that CDX-2 is a highly sensitive and specific marker to add
in a limited immunohistochemical panel for distinguishing
CDX-2–negative primary ovarian mucinous carcinomas from
CDX-2–positive secondary (intestinal) ovarian tumors.
These immunohistochemical results may be of impor-
tant clinical significance because most women with mucinous
ovarian tumors have a hidden intestinal carcinoma or have al-














Primary ovarian carcinomas 3/14 (21.42) 13/14 (92.85) 6/14 (42.85) 12/14 (85.71) 4/14 (28.57) 12/14 (85.71)
Secondary (intestinal) ovarian tumors 29/29 (100) 13/29 (44.82) 17/29 (58.62) 28/29 (96.55) 3/29 (10.34) 29/29 (100)
P/T, positive/total cases.
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ready undergone surgical treatment of a previous colorectal
tumor.28
The exact histologic diagnosis permits the best surgical
and chemotherapeutic treatment of the individual patient.
These results indicate the necessity, nevertheless, to investi-
gate the CDX-2 marker on a larger series of mucinous ovarian
lesions with known clinical history.
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